Why Choose Tirzepatide?

 

Tirzepatide represents the latest breakthrough in weight management and diabetes treatment. As a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, it offers unprecedented results for patients seeking effective, long-term solutions.

​

Real Patient Success:

"I lost 45 pounds in 6 months with Tirzepatide. My energy is back, my diabetes is under control, and I feel like myself again." - Sarah M.

​

Mechanism of Action

• GLP-1 Receptor Activation: Stimulates insulin secretion in a glucose-dependent manner, suppresses glucagon release, and slows gastric emptying

• GIP Receptor Activation: Enhances insulin sensitivity and may have direct effects on fat metabolism

• Appetite Regulation: Acts on brain receptors to reduce appetite and food intake

• Gastric Motility: Slows gastric emptying, leading to increased satiety

 

Transformative Results

 

Diabetes Management:

• Significant reduction in HbA1c levels

• Improved glycemic control

• Low risk of hypoglycemia

• Cardiovascular benefits

​

Weight Management Success:

• Average weight loss of 15-22% in clinical trials

• Sustained weight reduction

• Improved body composition

• Reduction in waist circumference

​

Clinical Trial Highlights:

In the SURMOUNT trials, patients achieved an average of 20.9% weight loss at the highest dose - results that exceeded all expectations and set new standards in weight management therapy.

 

 

Administration

​

Injection Sites: Thigh, abdomen, or upper arm. Rotate injection sites with each injection.

​

 

Side Effects

Common (≥5%):

• Nausea (12-18%)

• Diarrhea (12-16%)

• Vomiting (6-12%)

• Constipation (6-7%)

• Abdominal pain (6-9%)

• Injection site reactions

 

Serious (Rare):

• Pancreatitis

• Gallbladder disease

• Kidney problems

• Severe hypoglycemia (when combined with insulin/sulfonylureas)

• Thyroid C-cell tumors (theoretical risk)

​

 

Contraindications and Precautions

 

Contraindications:

• Personal or family history of medullary thyroid carcinoma

• Multiple Endocrine Neoplasia syndrome type 2

• Known hypersensitivity to tirzepatide

 

Use with Caution:

• History of pancreatitis

• Severe renal impairment

• Diabetic retinopathy

• Pregnancy and breastfeeding​​